SIGA Technologies finished the last product order under its long-running United States stockpile contract in the second quarter, and the equity now trades as a cash-rich franchise waiting for a successor award that has not arrived. The mid-year print was profitable, but the comparison against last year's heavy oral deliveries to the Strategic National Stockpile makes the quarter look like a cliff rather than a franchise in motion. What changed is not the science of TPOXX, the smallpox antiviral that is still the company's only commercial product. What changed is that the procurement book that funded SIGA for eight years is now empty on the product side. The market is no longer paying for a multiyear delivery schedule. It is paying for optionality around the next United States award, a thin overseas order book, and a balance sheet that can fund the wait.
Cash still covers more than half the equity value after a special dividend of sixty cents a share in April, and the company carries essentially no bank debt. Product sales in the quarter came from a late intravenous delivery into the stockpile plus oral courses sold to two overseas health ministries. That mix is less lucrative than last year's oral stockpile wave, which is why operating profit compressed even as the company stayed in the black. International demand is real but episodic, and it does not yet replace a multiyear United States award. A reader who treats the second-quarter rebound from a near-empty first quarter as evidence that the franchise has already reloaded is reading the wrong comparison. The right comparison is last year's stockpile year, and on that measure the earnings power has stepped down.
The investment debate is whether a new Administration for Strategic Preparedness and Response award, plus a thin book of overseas options, can restore the earnings power the market used to capitalize when the existing BARDA contract still had product left to ship. Management cites leadership turnover at Health and Human Services and a shift of contracting from the Biomedical Advanced Research and Development Authority to the stockpile office as reasons the process is slower than prior cycles. The next several quarters resolve whether that delay is bureaucratic or a signal that replenishment is smaller and later than bulls assume. Until a signed successor award is on the page, the equity is a cash stub plus a call on government timing.